PTC Therapeutics, Inc. (NASDAQ:PTCT) has received a consensus recommendation of “Hold” from the twelve ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, eight have given a hold rating and two have given a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $18.14.

Several analysts recently issued reports on PTCT shares. Cowen reiterated a “hold” rating on shares of PTC Therapeutics in a research report on Wednesday, October 25th. Citigroup reiterated a “buy” rating and set a $28.00 price target on shares of PTC Therapeutics in a research report on Wednesday, September 27th. ValuEngine lowered shares of PTC Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, September 7th. Barclays reiterated a “hold” rating and set a $22.00 price target on shares of PTC Therapeutics in a research report on Friday, September 8th. Finally, Zacks Investment Research lowered shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th.

PTC Therapeutics (PTCT) traded down $0.45 during midday trading on Monday, hitting $16.25. 571,373 shares of the company traded hands, compared to its average volume of 1,020,993. The company has a current ratio of 3.08, a quick ratio of 2.97 and a debt-to-equity ratio of 0.98. PTC Therapeutics has a twelve month low of $8.12 and a twelve month high of $22.00.

A number of large investors have recently modified their holdings of the stock. Alps Advisors Inc. lifted its stake in PTC Therapeutics by 5.6% in the 2nd quarter. Alps Advisors Inc. now owns 31,191 shares of the biopharmaceutical company’s stock valued at $572,000 after purchasing an additional 1,667 shares during the last quarter. Voya Investment Management LLC lifted its stake in PTC Therapeutics by 12.8% in the 2nd quarter. Voya Investment Management LLC now owns 16,459 shares of the biopharmaceutical company’s stock valued at $302,000 after purchasing an additional 1,866 shares during the last quarter. ProShare Advisors LLC raised its stake in shares of PTC Therapeutics by 8.9% during the second quarter. ProShare Advisors LLC now owns 24,115 shares of the biopharmaceutical company’s stock valued at $442,000 after acquiring an additional 1,970 shares during the last quarter. TIAA CREF Investment Management LLC raised its stake in shares of PTC Therapeutics by 3.0% during the first quarter. TIAA CREF Investment Management LLC now owns 96,318 shares of the biopharmaceutical company’s stock valued at $948,000 after acquiring an additional 2,774 shares during the last quarter. Finally, Teachers Advisors LLC raised its stake in shares of PTC Therapeutics by 5.2% during the second quarter. Teachers Advisors LLC now owns 61,324 shares of the biopharmaceutical company’s stock valued at $1,124,000 after acquiring an additional 3,026 shares during the last quarter. 86.18% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “PTC Therapeutics, Inc. (PTCT) Given Average Recommendation of “Hold” by Analysts” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.watchlistnews.com/ptc-therapeutics-inc-ptct-given-average-recommendation-of-hold-by-analysts/1758244.html.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.

Analyst Recommendations for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.